Pharmaceuticals
Celltrion USA announces U.S. launch of denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo)
* STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of PROLIA® (denosumab) and XGEVA® (denosumab) respectively[1],[2] * STOBOCLO and OSENVELT, among the first wave of biosimilars referencing PROLIA and XGEVA respectively, are commercially availa...
2025-07-08 10:08
2251
SCG Cell Therapy Announces Clearance of Investigational New Drug Application by the China NMPA for SCG101V
SINGAPORE, July 8, 2025 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases and associated cancers, announced today that the China National Medical Products Administration (NMPA) has cleared the Investigation...
2025-07-08 10:02
3651
WuXi AppTec Receives MSCI ESG AAA Leader Rating
SHANGHAI, July 7, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, today announced it has achieved the AAA rating – the highest level – from MSCI in its lates...
2025-07-07 20:08
2011
Nuevocor Strengthens Board with Appointment of Thierry Abribat
SINGAPORE, July 7, 2025 /PRNewswire/ -- Nuevocor
2025-07-07 13:00
1626
ESG | HitGen Releases Its Inaugural Sustainability Report
CHENGDU, China, July 4, 2025 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) today announced the release of its inaugural sustainability report, aiming to present the company's philosophies and policies in environmental, social, and governance ("ESG")...
2025-07-04 19:00
4615
Everest Medicines Showcases Breakthroughs in Proprietary AI-Powered mRNA Platform at 2025 R&D Day Held in Shanghai
SHANGHAI, July 4, 2025 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative medicines, recently hosted the "2025 Everest Medicines mRNA Platform R&D Day" in Shanghai. The e...
2025-07-04 16:58
3430
Kexing Biopharm Makes Its Debut at CPHI 2025, Followed by the 2025 International Pharmaceutical Cooperation High-End Forum, One of the Kexing Biopharm's Series of Globalization Activities in Shanghai
SHENZHEN, China, July 4, 2025 /PRNewswire/ -- Recently, Kexing Biopharm made a remarkable appearance at CPHI & PMEC China 2025 and successfully organized the 2025 International Pharmaceutical Cooperation High-End Forum, one of the Kexing Biopharm's series of globalization activities in Shanghai. ...
2025-07-04 16:26
4668
Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China
* Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater China * Brii Biosciences retains ex-Greater China rights to address the global antimicrobial resistance threats and continues investment in other priority pipeline assets DURHAM, N.C. and BEIJING, J...
2025-07-04 08:30
3754
Fangzhou Tops China's App Store Chart for Healthcare Apps
GUANGZHOU, China, July 3, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, earned the top spot in theJune 2025 China AppStore Healthcare TOP100 Free APP Rankings with its Fangzhou Online Pharmacy App, according to a report by ...
2025-07-03 18:43
2361
MOTE Therapeutics Taps MaryJane Rafii as Chief Investment & Business Officer to Drive Global Growth of RNA Delivery Platform
BOSTON, July 3, 2025 /PRNewswire/ -- MOTE Therapeutics (referred as MOTE), a seed-stage biotech developing targeted RNA delivery solutions, announced the appointment ofMaryJane Rafii, PhD, MBA, as Chief Investment and Business Officer. The move comes as MOTE accelerates development of its MOBILIZ...
2025-07-03 18:07
2328
Akeso's First Bispecific ADC (Trop2/Nectin4 ADC) Enters Clinical Trials, Strengthening Leadership in 'IO+ADC' 2.0 Strategy
HONG KONG, July 3, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") has announced the successful enrollment of the first patient in its Phase Ia clinical trial for AK146D1, a bispecific Antibody-Drug Conjugate (ADC) targeting Trop2 and Nectin4. AK146D1 is Akeso's first bispec...
2025-07-03 14:46
2510
Dizal's ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
* ZEGFROVY is the only approved targeted oral treatment for NSCLC with EGFR exon20ins * Approval follows the U.S. FDA's Priority Review and is supported by the pivotal WU-KONG1 Part B study, in which ZEGFROVY demonstrated statistically significant and clinically meaningfulbenefits to patien...
2025-07-03 08:08
2384
Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001
Highlights: * Neurizon® Therapeutics and Elanco Animal Health enter into an exclusive global licensing agreement * Provides worldwide rights for Neurizon to utilise Elanco's intellectual property, providing exclusive access to an extensive package of non-clinical studies and manufacturing da...
2025-07-03 07:09
2783
Ascletis Announces First Participants with Obesity or Overweight Dosed in a U.S. 13-week Phase IIa Study of Small Molecule Oral GLP-1R Agonist ASC30
- First participants with obesity or overweight with at least one weight-r elatedcomorbidity have been dosed in a U.S. 13-week Phase IIa study of small m oleculeoral GLP-1 receptor agonist ASC30. - ASC30 oral once-daily tablet demonstrated up to 6.5% placebo-adjusted mean body weight reduction f...
2025-07-03 07:00
2320
[iNtRON] Files U.S. Patent for Three Novel Endolysin-Based Drug Candidates Targeting Gram-Negative Bacteria
* Gram-negative bacterial infections are becoming an increasingly serious global health issue * U.S. patent applications filed for three novel drug candidates: PKL200, TSL2200, and EAL2200 * Continued diversification of business initiatives to address Gram-negative bacterial threats BOSTON ...
2025-07-02 20:00
2184
Everest Medicines Announces Updated Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy
* As of March 21st, 2025, longer follow-up data was collected from the ongoing Ph1b/2a study of EVER001: in Cohort 1, 11 patients completed 52 weeks of follow-up. In Cohort 2, 7 patients completed 52 weeks of follow-up. * The updated data showed that EVER001 was well-tolerated and efficacious ...
2025-07-02 15:33
2250
Seegene Launches STAgora™, a New Platform for Infectious Disease Analytics
* Real-time analytics that empower clinical decision-making and pandemic preparedness * Global unveiling at ADLM 2025 in Chicago to initiate business partnerships * Powered by AI and syndromic PCR to enable early detection and predictive insights SEOUL, South Korea, July 1, 2025 /PRNewswire/...
2025-07-01 22:09
3845
FAIR PLAY MENARINI INTERNATIONAL AWARD, LUIS FIGO JOINS THE GREAT SPORTS STARS ACKNOWLEDGED IN 2025
FLORENCE, Italy, July 1, 2025 /PRNewswire/ -- Surprises never end when it comes to theFair Play Menarini International Award: Luís Figo, European football legend and true icon of sporting integrity, will be among the awardees of the 29th edition of the event, taking place onJuly 2nd and 3rd in Fl...
2025-07-01 21:10
2958
WuXi XDC Announces the Mechanical Completion of its Singapore Site, Accelerating the Global Expansion of Bioconjugates Manufacturing
SHANGHAI and SINGAPORE, July 1, 2025 /PRNewswire/ -- On June 30, WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, announced that the mechanical completion of its ma...
2025-07-01 17:44
4619
HanchorBio and Henlius Sign Major Licensing Deal for HCB101 to Expand Global Immuno-Oncology Reach
TAIPEI and SHANGHAI and SAN FRANCISCO, July 1, 2025 /PRNewswire/ -- HanchorBio Inc. (7827.TWO), a global clinical-stage biotechnology company developing innovative immunotherapies for oncology and autoimmune diseases, today announces the signing of a major out-licensing agreement with Shanghai He...
2025-07-01 13:40
2384
Week's Top Stories
Most Reposted
Tetra Pak Opens Product Development Centre in Thailand, Unlocking A World of Possibilities for Food and Beverage Innovators Across Asia Pacific
[Picked up by 311 media titles]
2026-03-27 11:15
Visa Working Capital Index: Asia Pacific CFOs Call for Flexible, Digital Finance Solutions
[Picked up by 309 media titles]
2026-03-24 14:00Indonesia's P2P Lending Grows 25%, JULO Strengthens Credit Quality
[Picked up by 300 media titles]
2026-03-26 18:18
ART CENTRAL COMMENCES DISCOVERY-LED ELEVENTH EDITION
[Picked up by 277 media titles]
2026-03-25 16:51
RoboSense Beat Expectations, Achieved First-Ever Quarterly Profit on Strong Robotics Growth
[Picked up by 269 media titles]
2026-03-25 22:51
Most Read
Everbright Environment Announces 2025 Annual Results
2026-03-20 23:14
8166
Ten Pao Group Announces 2025 Annual Results
2026-03-20 23:35
7927
FiEE, Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results
2026-03-21 04:05
7919
U Power Limited Announces Closing of $6.0 Million Public Offering
2026-03-21 02:40
7405